Aim:Tb compare the efficacy of electroconvulsive therapy (ECT) with risperidone in the treatment of lorazepam non-responsive catatonia. Materials and methods: Inpatients with non-affective catatonia (n= 18) non-responsive to at least five-day trial of lorazepam (6-8 mg/day) were randomised into two groups in a double blind randomised design. Written informed consent was obtained. Four were dropped from the trial as they were found to have depressive catatonia. One group received true ECT (thrice weekly, n=8) plus oral placebo while the other received sham ECT plus risperidone (4-6 mg/ day). Bush-Francis Catatonia Rating Scale (BFCRS) was administered twice weekly to assess improvement in catatonic symptoms over a period of three weeks. The two groups were compared using two-way RMANOVA. Results: BFCRS scores reduced markedly over treatment course and this reduction was more profound in the ECT group (p=0.035). Shorter the duration of illness greater was the response (lower scores of BFCRS). Conclusions: Superior clinical efficacy of ECT over neuroleptics in catatonia is confirmed by this randomized clinical trial.
INTRODUCTION
.Catatonia is a syndrome of motor abnormalities in association with disorder of mood, behaviour or thought (Mahendra, 1981) . Catatonia is both a symptom and diagnosis by itself. It is a medical emergency. A detailed review of organic conditions producing catatonia is described elsewhere (Ahuja, 2000) . Functional illnesses, which produce catatonia, include mood disorder (mania and depression), schizophrenia and/ <>r dissociation. Rarely it can be a manifestation of other psychiatric illness such as obsessive-compulsive disorder (Jagadccshan et al, 2002) . Benzodiazepine, particularly lorazepam, is the treatment of choice in functional catatonia (Greenfield ct al, 1987; Bush et al, 1996a; Payee et al, 1999) . Nearly "0-80% of the patients improve within 48-72 hours of lorazepam trial (6-8mg/day). Electroconvulsive therapy (ECT) is an alternative form of treatment in catatonia. ECT is found to be useful in lorazepam non-responsive catatonic patients (Rohland et al, 1993; Bush et al, 1996a) . Catatonic symptom in severe depression also had a good prediction to ECT response (Abrams, 1997; Joseph, 1999) . Many psychiatrists consider catatonia as a subtype of schizophrenia and have therefore used neuroleptic drugs with success (Joseph, 1999) . Other agents used in the treatment include amobarbital, lithium and carbamazepinc (Abrams and Taylor, 1976; Abrams, 1997) . However their use is limited in clinical practice. There arc also no comparative trials with these agents in the treatment of catatonia. This study compared the efficacy of FX7T over antipsychotic drug -risperidone
MATERIALS AND METHODS

Subjects
Drug naive inpatients (n=68) with a diagnosis of non-atfective functional catatonia were considered for the trial. The clinical diagnosis (1CD-10; WHO, 1992) was made based on the detailed history obtained from patient's relatives and previous records. Consent for the study was obtained from the spouse or a nearest family member and also from the patient during the study period when he was able to provide consent. The psychiatry department at National Institute of Mental Health and Neruosciences, Bangalore approved the study protocol.
Treatment
Patients in ECT group received bilateral Patients in risperidone group received oral risperidone in BID doses, 2mg per day (day-1) and that was increased to 4 to 6mg over two to tour days until patient developed subtle extrapyramidal symptoms (ITS). Sham KCT was administered at thrice weekly KCT using intravenous thiopentone (4mg/ kg bodv weight). The Bl' cuff was tied in the right leg and the KEG electrodes were applied over the scalp in sham KCT patients too.
Rating scales
In lorazepam non-responsive patients (n -IS), the clinical diagnosis was confirmed by clmic.il interview (ICD-10; WHO, 1992) by another psychiatrist (CiK) at baseline and during the studs' period.
Patients were evaluated for catatonic signs severity using BushTrancis Catatonia Rating Scale (BI'CRS; Bush et al, 1996b) adminMcrcd before KCT (baseline) and twice weekly thereafter. Another psychiatrist tllK': administered BI'CRS on the fifth day of lorazepam treatment. Patients who had no or only one catatonic sign on BI'CRS were termed 'respoiulers'. Those who had more than one were termed 'non-responsive' and continued in the trial.
Psvchopathologv was assessed once every week using Positive and Negative Syndrome Scale (J'ANSS; Kay et al. P>8~ ). PANSS svas not administered at baseline (as formal interviesv was not possible). Scores were available in only eight patients at the end of one week and for all patients at the end of second and third sveek.
Columbia side-effect checklist (Sackeim et al, 1987) for KCT-induced side effects and Simpson-Angus rating scale (Lejos'cux et al, 1993) for risperidonc-induced extrapyramidal side effects were administered once every week in all patients. A single psychiatrist ((INS) administered all the above rating scales through out the study period. He svas blind to randomisation.
Statistics
Fisher's test svas used to compare the demographic and clinical characteristics of the patients between the KCT group and risperidone group. The diagnostic agreement between the two raters in 18 patients svas assessed by Kappa. The interrater reliability on baseline BI'CRS score was measured by intraclass correlation. Tsvo-svay RMANOVA was used to compare the BI'CRS scores between the ECT group and risperidone group over thrce-sveek period. Similarly PANSS scores as-ailable at the end of second and third week svere compared between the two groups using two-way RMANOVA. 
RESULTS
All subjects (n=14) completed the 3-wcek study period. The demography and clinical data of the KCT and risperidone groups arc given in Table- (Fig-1) 
There was higher incidence of headache (n=6) and transient memory impairment (n=4) in F.CT group. There was no major on-the-table complication with ECT except one having prolonged seizures at two ECT sessions (aborted using 5mg intravenous diazepam). Two patients in risperidone group I had tremors and mild rigidity and received trihexyphenydyl (2-4mg/day) along with risperidone. One had akathisia but no additional intervention was needed clinically.
None had dystonia or neuroleptic malignant syndrome.
DISCUSSSION
The results of this study demonstrated that ECT was more efficacious than risperidone in the treatment of non-affective catatonia non-responsive to lorazepam. BFCRS and PANSS scores improved more with F.CT than risperidone and were statistically significant. To our knowledge this is the only double blind randomised study that has compared two different treatments in catatonia. Hence no comparison is possible. The study consisted of a homogenous group of non-affective catatonic patients from a representative inpatient sample. There was high interrater reliability in clinical diagnosis and baseline BFCRS scores.
Most of the catatonic patients (73.5%) improved with lorazepam and within 48-72 hours. This response was in comparison to earlier studies (Greenfield et al, 1987; Ungavari et al, 1994; Bush et al, 1996; Payee et al, 1999) . On comparison with the nonresponders (n=18), the earlier group had relatively short duration of catatonia (12.5 weeks v/s 38.4 weeks) and were largely males (38 v/s 3).
Unlike lorazepam, which is useful in ameliorating the catatonic signs, ECT also produced marked improvement in underlying psychiatric illness. The PANSS scores improved better with ECT compared to risperidone. Positive symptoms improved more than negative symptoms.
Univariate analysis was attempted to examine predictors of response in catatonia. Patients treated with ECT and shorter duration of catatonia had lower BFCRS scores at the end of three-week. There was no association between the number of catatonic signs and outcome. These findings support earlier observations (Rosebush et al, 1992; Bush et al, 1996) .
Response to ECT was dramatic in catatonia in previous studies (Rosebush et al, 1992; Bush et al, 1996) . The average number of ECT ranged from 2-4 and clinical improvement was marked. In our study though patients improved with F.CT. the average number of ECT was 8.87 (range 6-13) in ECT group. We deliberately selected non-affective catatonia. Nearly 65% of the patients in previous studies had affective illness (Bush et al, 1996) . Secondly the duration of catatonia prior to entry in their study was less than a week while it was 38.4 weeks in our study.
Catatonia scores reduced significantly in the F.CT group. However four out of eight patients continued to receive ECT beyond a three-week period (10-13 ECT) though Some have argued that addition of neuroleptics in catatonic patients may precipitate catatonic signs (Gercnbcrg, 1977; Taylor, 1990) . There is also risk of NMS (Mann ct al, 1986; Philbrick and Rumnans, 1994) which is life threatening. However, none in our sample had any such serious effects. However, one has to be cautious and watch for such symptoms and gradually increase neuroleptics if preferred over ECT. 
